Biogen shares dropped 8.4 percent as investors were hoping for a bigger breakthrough.
A new investigational antipsychotic drug, ITI-007, entered its phase 3 study with some promising results. According to Medscape, the findings from an earlier large phase 2b trial proved that the investigative drug